Table 1.
Summarization and univariate Cox-pH analysis of clinical factors for overall survival.
| Features | Grades | Median (IQR) or No (%) | HR (95%CI) | P value |
|---|---|---|---|---|
| OS (months) | 25.78 (14.26 – 41.57) | |||
| Censor | 0 | 103 (80.47%) | ||
| 1 | 25 (19.53%) | |||
| Age (years) | 53 (46 – 63) | 0.08 (9.08e − 04 – 6.87) | 0.27 | |
| ECOG | 0 and 1 | 112 (87.5%) | Reference | |
| 2 | 16 (12.5%) | 1.74 (0.65 – 4.65) | 0.27 | |
| FIGO 2018 stage | II | 36 (28.12%) | Reference | |
| III | 83 (64.84%) | 1.82 (0.61 – 5.43) | 0.28 | |
| IV | 9 (7.03%) | 5.82 (1.44 – 23.48) | 0.01 | |
| Body mass index | 23.05 (20.11 – 25.01) | 1.06e − 03 (1.75e − 06 – 0.65) | 0.04 | |
| EBRT technique | 3D-CRT | 27 (21.09%) | Reference | |
| RapidArc | 101 (78.91%) | 0.9 (0.38 – 2.14) | 0.81 | |
| Induction chemotherapy | Without | 102 (79.69%) | Reference | |
| With | 26 (20.31%) | 1.4 (0.52 – 3.8) | 0.51 | |
| Concurrent chemotherapy | Without | 20 (15.62%) | Reference | |
| With | 108 (84.38%) | 0.7 (0.24 – 2.05) | 0.52 | |
| Pre-RT regional lymph node metastasis | Without | 43 (33.59%) | Reference | |
| With | 85 (66.41%) | 1.48 (0.62 – 3.57) | 0.38 | |
| White blood cells (103 cells/ul) | 6.59 (5.12 – 8.12) | 1.85 (0.23 – 14.72) | 0.56 | |
| Hemoglobin (g/L) | 117.5 (102.5 – 129.25) | 8.96e − 04 (4.34e − 06 – 0.18) | 9.84e-03 | |
| Platelets (103 cells/ul) | 260 (217.5 – 318) | 2.29 (0.17 – 30.44) | 0.53 | |
| Neutrophils (103 cells/ul) | 4.24 (3.03 – 5.65) | 2.61 (0.51 – 13.42) | 0.25 | |
| Lymphocytes (103 cells/ul) | 1.74 (1.3 – 2.08) | 0.11 (9.11e − 03 – 1.22) | 0.07 | |
| Monocytes (103 cells/ul) | 0.34 (0.25 – 0.44) | 0.34 (0.06 – 1.94) | 0.22 |
Abbreviations: OS = overall survival; EBRT = external beam radiation therapy; 3D-CRT = three-dimensional conformal radiotherapy; RT = radiotherapy; ECOG = Eastern Cooperative Oncology Group; FIGO=International Federation of Gynecology and Obstetrics; IQR = interquartile range; HR = hazard ratio; CI = confidence interval.